ACell + PRP Hair Loss Therapy is an exciting non-surgical option for both men and women experiencing hair loss.
This treatment is not for all patients and Dr. McGarth will personally diagnose your hair loss history before recommending this as a treatment option. Dr. McGrath has been one of the pioneers in ACell plus platelet rich plasma (PRP) combination injection therapy and has had great success with qualified candidates. Acell MatriStem is “porcine urinary bladder matrix,” derived from pig bladder cells, that has proven to be very helpful in wound healing. Wound healing has been at the forefront of research into hair cloning and hair follicle regeneration.
ACell – 1 year hair regrowth progression.
At the 19th annual conference of the International Society of Hair Transplant Surgeons, evidence was presented that Acell “attracts” adult stem cells to a “wound” and converts them into the progenitor cells that, in the case of hair follicles, actually grow hair. So, the idea is to combine Acell with large amounts of adult stem cells taken from the patient’s own body — which is where the Platelet Rich Plasma (PRP) comes in — and then to inject this into the thinning hair areas of the scalp. The hope is that it will send signals to the adult stem cells lurking in the dormant hair follicles and, in essence, wake them up.
Dr. McGrath began treating select patients with a combination of ACell plus Platelet Rich Plasma. The initial results have been very encouraging and we are expanding treatment for both men and women and in combination with hair transplant surgery. This has been particularly exciting for women who until now had few options for treating genetic hair loss.
ACell and Dr McGrath in the News
About ACell MatriStem®
ACell’s MatriStem® technology is a naturally occurring, non-crosslinked, completely resorbable, acellular material. MatriStem devices are unique from other scaffold technologies in that they fundamentally change healing by triggering abundant new blood vessel formation and recruiting numerous cell types to the site of injury. It appears that these cells, including progenitor cells, have the potential to differentiate into numerous types of site specific tissues. During the healing process, the scaffold is degraded and completely resorbed, leaving new tissue where scar tissue would normally be expected. This proprietary UBM scaffold technology can be used in a broad range of medical applications such as wound care, general surgery, gastrointestinal surgery, urology and plastic and reconstructive surgery.